Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?
Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.
Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption
Samsung Bioepis presented new SB16 subgroup data at WCO 2026. Read what it means for Obodence adoption, biosimilar trust, and osteoporosis care.
Early-stage biosimilar deal between Samsung Bioepis and Sandoz covers vedolizumab and four undisclosed molecules
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
Samsung Bioepis takes over BYOOVIZ commercialization in Europe after Biogen exit
Samsung Bioepis has officially begun direct commercialization of BYOOVIZ, a biosimilar to Lucentis (ranibizumab), across Europe following the complete transfer of rights from Biogen. The move makes BYOOVIZ the fourth biosimilar now independently marketed by Samsung Bioepis in the region, joining EPYSQLI (eculizumab), OBODENCE (denosumab), and XBRYK (denosumab). The company also confirmed that a pre-filled […]
Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia’s biosimilar adoption. Find out what this means.